IL‑37 drives temozolomide resistance in glioblastoma via MAPK pathway activation
Oncology Letters · 03.06.2026 · 32 (2) · 1-14
DOI: 10.3892/ol.2026.15677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Letters, online erschienen am 03.06.2026. Verfasst von Yu Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China.
- Department of Neurology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China.
- College of Pathology, Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China.
- Department of Radiotherapy, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China.
Zitieren
APA
Wang, Y., Liu, Y., Wang, J., Rong, W., & Song, X. (2026). IL‑37 drives temozolomide resistance in glioblastoma via MAPK pathway activation. Oncology Letters, 32(2), 1-14. https://doi.org/10.3892/ol.2026.15677
Vancouver
Wang Y, Liu Y, Wang J, Rong W, Song X. IL‑37 drives temozolomide resistance in glioblastoma via MAPK pathway activation. Oncology Letters. 2026;32(2):1-14. doi:10.3892/ol.2026.15677
BibTeX
@article{Wang2026,
author = {Wang, Yu and Liu, Ying and Wang, Jingyi and Rong, Wei and Song, Xue},
title = {IL‑37 drives temozolomide resistance in glioblastoma via MAPK pathway activation},
journal = {Oncology Letters},
year = {2026},
volume = {32},
number = {2},
pages = {1--14},
doi = {10.3892/ol.2026.15677}
}
EUVIMED